Lv2
190 积分 2025-04-14 加入
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review
8小时前
已完结
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia
7天前
已完结
TRANSCEND: A Phase 3 Trial of the Anti-CD38 Antibody Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection
10天前
已关闭
Anti-angiogenesis enhances the tumor immunotherapeutical effect of recombinant CD80 fusion protein
2个月前
已完结
Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma
3个月前
已关闭
Safety, Tolerability, and Efficacy of Mezagitamab (TAK-079) as Add-On to Standard-of-Care Therapy in Individuals with Primary IgAN: Week 96 Data from an Open-Label Phase 1b Study
3个月前
已关闭
Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia
3个月前
已完结
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
5个月前
已完结
Tremelimumab: First Approval
5个月前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
6个月前
已完结
皖公网安备34019202002308
